[ PROJECT DRoNE ]

ALTITUDE: STRATOSPHERIC

LAT: BC // LONG: 2026

Project DRoNE:
Navigating the Pipeline
Horizon

From Static News to Dynamic Navigation

Static News

ACQUIRED:
INACTIVE DATA

302010

Dynamic Navigation

TARGET LOCK:
ACTIVE INTELLIGENCE

300200100

Traditional media, retrospective analysis, limited scope.

Real-time insights, strategic foresight, molecular precision.

Mission Parameters

The Pilot You.

HR+ Breast Cancer Landscape

75–80%

of all Breast Cancer cases

Inavolisib

Pink wireframe mountain representing the project pipeline

Mechanism of action

PI3CA mutation

INAVO 120 (efficacy)

INAVO 120 (safety)

Guidelines & Future algorithm

Approvals

Mission Debrief

The PI3K Pathway Imperative

35–40%

PIK3CA
mutations in
HR+ cases

[ SCANNER ACTIVE ]

Prevalence PI3K/AKT pathway alterations are highly common across HR+ breast cancer cases.

Prognostic Warning Alterations are associated with poor prognosis in metastatic breast cancer (mBC).

            Key Driver
            PI3K is the key upstream regulator of AKT/mTOR — the master switch of this pathway.
          

Navigation: Standard of Care (1L).

HR+, HER2− mBC

↓

PIK3CA-mutated

↓

ESMO Recommended Option

Inavolisib + Palbociclib + Fulvestrant

NCCN Category 1 Preferred

Global Authorization: Guidelines & Approvals

FDA Approved — PIK3CA-mutated, endocrine-resistant, HR+/HER2− LA/mBC

EMA Approved — PIK3CA-mutated, endocrine-resistant, HR+/HER2− LA/mBC

Mission Debrief.

New Standard

Inavolisib is the SoC for 1L PIK3CA-mutated HR+ breast cancer.

Double Benefit

Doubled PFS and significant OS improvement (Delta 7 months).

Future Ready

Giredestrant is the next major landmark in HR+ care.

On the Horizon: Giredestrant.

Scanning...

0 SCALE: 10,000 10000

The Scientific Radar: Recent Transmissions

> INAVO120 Primary Manuscript — [Link Available]

> INAVO120 OS Manuscript — [Link Available]

> ESMO 2025: Mayer EL, et al. (Oral LBA16)

> SABCS 2025: Bardia A, et al. (Oral GS1-02)

Project DRoNE: Navigating the Pipeline Horizon